Carnegie Capital Asset Management LLC Trims Holdings in Johnson & Johnson (NYSE:JNJ)

Carnegie Capital Asset Management LLC decreased its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 5.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 168,726 shares of the company's stock after selling 9,150 shares during the quarter. Johnson & Johnson accounts for about 0.9% of Carnegie Capital Asset Management LLC's holdings, making the stock its 23rd biggest holding. Carnegie Capital Asset Management LLC's holdings in Johnson & Johnson were worth $26,446,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. DORCHESTER WEALTH MANAGEMENT Co raised its holdings in Johnson & Johnson by 8.6% in the first quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 67,618 shares of the company's stock valued at $14,975,000 after acquiring an additional 5,327 shares in the last quarter. Cantor Fitzgerald Investment Advisor L.P raised its holdings in Johnson & Johnson by 88.9% in the first quarter. Cantor Fitzgerald Investment Advisor L.P now owns 175,194 shares of the company's stock valued at $31,049,000 after acquiring an additional 82,429 shares in the last quarter. AMI Investment Management Inc. raised its holdings in Johnson & Johnson by 8.8% in the first quarter. AMI Investment Management Inc. now owns 18,305 shares of the company's stock valued at $3,244,000 after acquiring an additional 1,475 shares in the last quarter. Equitable Holdings Inc. raised its holdings in Johnson & Johnson by 4.9% during the first quarter. Equitable Holdings Inc. now owns 45,673 shares of the company's stock worth $8,095,000 after purchasing an additional 2,119 shares in the last quarter. Finally, USS Investment Management Ltd raised its holdings in Johnson & Johnson by 2.4% during the first quarter. USS Investment Management Ltd now owns 860,371 shares of the company's stock worth $152,488,000 after purchasing an additional 20,528 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 59,397 shares of the business's stock in a transaction on Friday, February 9th. The shares were sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the sale, the executive vice president now directly owns 141,416 shares in the company, valued at approximately $22,099,078.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, EVP Jennifer L. Taubert sold 59,397 shares of the business's stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the sale, the executive vice president now directly owns 141,416 shares in the company, valued at approximately $22,099,078.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder & Johnson Johnson sold 3,725 shares of the business's stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the sale, the insider now owns 4,099,575 shares in the company, valued at $105,810,030.75. The disclosure for this sale can be found here. Insiders own 0.16% of the company's stock.

Johnson & Johnson Stock Performance

NYSE:JNJ traded up $2.17 during midday trading on Friday, reaching $147.91. The stock had a trading volume of 9,750,751 shares, compared to its average volume of 7,172,391. The firm has a fifty day simple moving average of $156.15 and a two-hundred day simple moving average of $155.63. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $175.97. The company has a quick ratio of 0.91, a current ratio of 1.16 and a debt-to-equity ratio of 0.38. The stock has a market cap of $356.43 billion, a P/E ratio of 9.22, a P/E/G ratio of 2.40 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Tuesday, April 16th. The company reported $2.71 EPS for the quarter, topping the consensus estimate of $2.64 by $0.07. The company had revenue of $21.38 billion for the quarter, compared to analyst estimates of $21.39 billion. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.43%. The business's revenue was up 2.3% on a year-over-year basis. During the same period in the previous year, the firm earned $2.68 EPS. On average, equities analysts expect that Johnson & Johnson will post 10.65 EPS for the current year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Tuesday, May 21st will be given a dividend of $1.24 per share. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.19. This represents a $4.96 annualized dividend and a dividend yield of 3.35%. The ex-dividend date of this dividend is Monday, May 20th. Johnson & Johnson's payout ratio is presently 29.68%.

Wall Street Analyst Weigh In

A number of research firms have weighed in on JNJ. Raymond James raised their price objective on shares of Johnson & Johnson from $172.00 to $175.00 and gave the stock an "outperform" rating in a report on Wednesday, January 3rd. Royal Bank of Canada cut their price objective on shares of Johnson & Johnson from $181.00 to $175.00 and set an "outperform" rating on the stock in a report on Wednesday. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $215.00 target price on shares of Johnson & Johnson in a report on Monday, April 15th. HSBC raised shares of Johnson & Johnson from a "hold" rating to a "buy" rating and lifted their target price for the company from $169.00 to $170.00 in a report on Thursday. Finally, StockNews.com raised shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a report on Tuesday, February 6th. Seven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Johnson & Johnson currently has an average rating of "Moderate Buy" and an average target price of $175.86.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.